Literature DB >> 15761967

Cost-effective method of siRNA preparation and its application to inhibit hepatitis B virus replication in HepG2 cells.

Zhi-Kang Qian1, Bao-Qin Xuan, Tai-Shan Min, Jian-Feng Xu, Lin Li, Wei-Da Huang.   

Abstract

AIM: To find a cost-effective method of preparation of short interfering RNAs based on cloning, fermentation, digestion and purification (CFDP) and test its feasibility to inhibit hepatitis B virus replication in cell culture.
METHODS: We constructed an expression vector containing T7 and tac promoter in a head-to-head orientation. cDNA fragment of interest was cloned into this vector between the opposing promoters. dsRNAs were expressed with this vector in Escherichia coli, and purified by affinity chromatography using CF 11 column. They were digested by RNase III in a buffer containing manganese ions, then separated on 15% non-denaturing PAGE, and the siRNAs about 25 bp in length were recovered. siRNAs prepared with CFDP were co-transfected with target gene expression plasmid into human cell lines with lipofectamine 2,000 to test their inhibition efficiency.
RESULTS: siRNAs corresponding to part of the hepatitis B virus polymerase gene (siHBVP) prepared by CFDP specifically and dramatically suppressed the virus protein expression. The HBsAg expression level was reduced to 10% that of the control by co-transfection of 60 nmol/L siHBVP in SMMC7721 cells. Dose-dependent effect on suppression of HBsAg and HBeAg expression was observed in HepG2 cells. The highest inhibition rate was kept at 70% during the six days after transfection of 7.5 nmol/L siHBVP.
CONCLUSION: We show CFDP is a very promising method to prepare therapeutic agents in anti-virus applications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761967      PMCID: PMC4250676          DOI: 10.3748/wjg.v11.i9.1297

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells.

Authors:  S M Hammond; E Bernstein; D Beach; G J Hannon
Journal:  Nature       Date:  2000-03-16       Impact factor: 49.962

Review 2.  Management of chronic hepatitis B.

Authors:  Hari S Conjeevaram; Anna Suk-Fong Lok
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

3.  Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells.

Authors:  Dun Yang; Frank Buchholz; Zhongdong Huang; Andrei Goga; Chih-Ying Chen; Frances M Brodsky; J Michael Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-02       Impact factor: 11.205

4.  A simple and cost-effective method for producing small interfering RNAs with high efficacy.

Authors:  Muhammad Sohail; Graeme Doran; Johann Riedemann; Val Macaulay; Edwin M Southern
Journal:  Nucleic Acids Res       Date:  2003-04-01       Impact factor: 16.971

5.  Inhibition of hepatitis B virus replication by stably expressed shRNA.

Authors:  Ying Chen; Dan Du; Jun Wu; Chun-Pong Chan; Yuequi Tan; Hsiang-fu Kung; Ming-Liang He
Journal:  Biochem Biophys Res Commun       Date:  2003-11-14       Impact factor: 3.575

6.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

Review 7.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

8.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

9.  Selective inhibition of hepatitis B virus replication by RNA interference.

Authors:  Chunxiao Ying; Erik De Clercq; Johan Neyts
Journal:  Biochem Biophys Res Commun       Date:  2003-09-19       Impact factor: 3.575

10.  siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells.

Authors:  Karin Butz; Tutik Ristriani; Arnd Hengstermann; Claudia Denk; Martin Scheffner; Felix Hoppe-Seyler
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

View more
  7 in total

1.  esiRNAs purified with chromatography suppress homologous gene expression with high efficiency and specificity.

Authors:  Baoqin Xuan; Zhikang Qian; Chang Tan; Taishan Min; Shuiyuan Shen; Weida Huang
Journal:  Mol Biotechnol       Date:  2005-11       Impact factor: 2.695

2.  High doses of siRNAs induce eri-1 and adar-1 gene expression and reduce the efficiency of RNA interference in the mouse.

Authors:  Jie Hong; Zhikang Qian; Shuiyuan Shen; Taishan Min; Chang Tan; JianFeng Xu; Yingchun Zhao; Weida Huang
Journal:  Biochem J       Date:  2005-09-15       Impact factor: 3.857

3.  High-dose siRNAs upregulate mouse Eri-1 at both transcription and posttranscription levels.

Authors:  Yingnan Bian; Wei Zhou; Yingchun Zhao; Xiaoping Li; Wei Geng; Ruixin Hao; Qing Yang; Weida Huang
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

4.  A Simple and Cost-Effective Approach for In Vitro Production of Sliced siRNAs as Potent Triggers for RNAi.

Authors:  Guihua Sun; Arthur D Riggs
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-13       Impact factor: 8.886

5.  Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice.

Authors:  Lei Ye; Fangming Kan; Tao Yan; Jiaqi Cao; Leiliang Zhang; Zhijian Wu; Wuping Li
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

Review 6.  Hepatitis B Virus Research in South Africa.

Authors:  Mohube B Maepa; Abdullah Ely; Anna Kramvis; Kristie Bloom; Kubendran Naidoo; Omphile E Simani; Tongai G Maponga; Patrick Arbuthnot
Journal:  Viruses       Date:  2022-08-31       Impact factor: 5.818

Review 7.  Advances with RNAi-Based Therapy for Hepatitis B Virus Infection.

Authors:  Fiona van den Berg; Shonisani Wendy Limani; Njabulo Mnyandu; Mohube Betty Maepa; Abdullah Ely; Patrick Arbuthnot
Journal:  Viruses       Date:  2020-08-04       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.